U.S. Patent 6,974,590: Fentanyl Buccal, Sublingual, and Gingival Administration Patent Analysis

U.S. Patent No. 6,974,590 covers a method of administering fentanyl across the oral mucosa using a solid dosage form containing fentanyl, a saliva-activated effervescent agent, and a pH-adjusting substance. The independent claim is directed to the administration method, not to every fentanyl tablet or every oral transmucosal fentanyl product. Its commercial relevance is strongest for effervescent buccal tablets using a neutral or mildly alkaline microenvironment to improve fentanyl absorption.

The patent issued December 13, 2005, to Cima Labs, Inc. Its claim scope is narrower than the broad concept of buccal fentanyl. Products using a different absorption-enhancement mechanism, dosage form, route, or formulation may fall outside the claims. By 2026, the patent's ordinary 20-year term has ended, subject to the controlling USPTO patent-term-adjustment record.

What does U.S. Patent 6,974,590 protect?

The patent protects a specific administration process with five core technical requirements:

Fentanyl or a pharmaceutically acceptable fentanyl salt.
A solid oral dosage form.
Administration across the oral mucosa.
A saliva-activated effervescent agent present at about 5% to 80% by weight.
A pH-adjusting substance intended to support absorption.

Claim 1 covers buccal, sublingual, and gingival administration. Claims 2 through 4 narrow the route. Claim 5 limits the patient to a human. Claim 6 limits the dosage form to a tablet. Claims 7 through 9 further limit the pH-adjusting substance and the resulting local pH.

The patent does not claim fentanyl broadly, all fentanyl transmucosal products, or the use of fentanyl for breakthrough cancer pain without the specified formulation features.

What is the claim hierarchy?

Claim	Subject matter	Legal effect
1	Fentanyl solid dosage form, saliva-activated effervescent agent at about 5%-80% by weight, pH-adjusting substance, oral-mucosal administration	Independent method claim
2	Buccal administration	Narrows claim 1
3	Sublingual administration	Narrows claim 1
4	Gingival administration	Narrows claim 1
5	Human mammal	Narrows claim 1
6	Tablet dosage form	Narrows claim 1
7	pH-adjusting substance is a base	Narrows claim 1
8	pH-adjusting substance produces substantially neutral pH at the absorption site	Narrows claim 1
9	Substantially neutral pH is slightly above 7	Narrows claim 8

Because claims 2 through 9 depend on claim 1, an accused product must satisfy every limitation of claim 1 plus the additional limitation in the dependent claim.

How broad is claim 1 of U.S. Patent 6,974,590?

Claim 1 is technologically focused but commercially important. It combines structural, compositional, functional, and route-of-administration limitations.

Fentanyl requirement

The claim covers fentanyl and pharmaceutically acceptable salts. It does not require a particular fentanyl dose, particle size, polymorph, salt form, or release profile.

This language may cover fentanyl citrate and other pharmaceutically acceptable salts if the remaining claim limitations are met. A product containing a fentanyl analog rather than fentanyl itself would raise a separate literal-scope and possible doctrine-of-equivalents analysis.

Solid dosage-form requirement

The claim requires a solid oral dosage form. Tablets, compressed tablets, rapidly dissolving tablets, and potentially other solid forms can qualify.

The claim does not expressly require:

A specific tablet hardness.
A particular disintegration time.
A multilayer structure.
A mucoadhesive layer.
A particular fentanyl concentration.
A specific excipient.
A particular tablet weight.
A particular commercial indication.

A liquid, spray, patch, or conventional nasal dosage form generally would not satisfy the solid-dosage-form limitation.

Effervescent-agent requirement

The effervescent agent must be saliva activated and present in an amount between about 5% and 80% by weight.

The likely technical concept is an acid-base reaction initiated by saliva. Carbonate, bicarbonate, and organic-acid systems are typical examples, although infringement turns on the formulation and claim construction rather than the ingredient name alone.

The 5% to 80% range is a major limitation. A formulation containing less than approximately 5% or more than approximately 80% may avoid literal infringement, although the meaning of "about" could create a boundary dispute. The accused party would need formulation records, batch specifications, and analytical data to assess the range.

The phrase "in an amount sufficient to increase absorption" adds a functional limitation. A patent owner would likely need to show that the agent improves fentanyl absorption relative to an appropriate control or that the formulation operates in the claimed manner. The precise evidentiary burden would depend on claim construction and the infringement theory.

pH-adjusting-substance requirement

Claim 1 requires at least one pH-adjusting substance. Claim 7 narrows this limitation to a base. Claims 8 and 9 impose a functional pH result:

A substantially neutral pH at the absorption site.
A pH slightly higher than 7.

The relevant pH is not necessarily the pH of the dry tablet. The claim focuses on the environment at the site of mucosal absorption after exposure to saliva. This distinction matters because the formulation may have a different measured pH before hydration, during dissolution, or in a laboratory medium.

What products are most likely to fall within the patent scope?

The highest-risk product profile is an effervescent fentanyl buccal tablet that uses an alkaline or neutralizing system to increase transmucosal absorption.

Product profile	Potential relevance to 6,974,590
Effervescent fentanyl buccal tablet	Highest potential relevance
Effervescent fentanyl sublingual tablet	Potentially within claims 1 and 3
Effervescent fentanyl gingival tablet	Potentially within claims 1 and 4
Non-effervescent fentanyl buccal tablet	Lower risk under the stated claims
Fentanyl buccal film	Depends on whether it is a solid dosage form and uses the claimed effervescent system
Fentanyl sublingual spray	Generally outside the solid-dosage-form limitation
Fentanyl nasal spray	Outside the oral-mucosal route limitation
Transdermal fentanyl patch	Outside the route and dosage-form limitations
Conventional fentanyl lozenge	Depends on effervescent content and pH-adjustment system
Injectable fentanyl	Outside the claimed route and dosage form

The product's brand name is not determinative. A product marketed as buccal, sublingual, or oral transmucosal may still avoid the patent if it lacks the claimed effervescent system or does not meet the claimed weight range.

How do claims 2 through 9 affect infringement risk?

The dependent claims provide narrower fallback positions for the patent owner.

Buccal administration

Claim 2 is commercially significant because the principal product associated with the Cima oral-transmucosal technology was a buccal fentanyl tablet. The claim requires the administration route to be buccal but does not add a dose or indication limitation.

Sublingual and gingival administration

Claims 3 and 4 extend the route coverage beyond buccal administration. They could be relevant to sublingual tablets or dosage forms placed against gingival tissue, provided claim 1's effervescent and pH limitations are met.

Human administration

Claim 5 has limited commercial value because most marketed fentanyl products are intended for human use. It may have evidentiary value where the accused conduct involves clinical or commercial administration to patients.

Tablet limitation

Claim 6 narrows claim 1 to tablets. A tablet developer may face greater risk under claim 6 than under claim 1 only if the dosage form clearly qualifies as a tablet. The limitation does not require a particular manufacturing process.

Base and neutral-to-alkaline pH

Claims 7 through 9 are technically narrower but may align closely with formulations designed to exploit fentanyl's pH-dependent transmucosal absorption. They can be important where the accused formulation contains bicarbonate, carbonate, hydroxide, or another basic excipient.

What is the patent's prosecution and legal scope?

The patent is a method-of-use patent with formulation limitations. That structure creates two enforcement paths:

Direct infringement through administration of the claimed dosage form.
Induced infringement through labeling, instructions, training, or other conduct encouraging the claimed administration method.

A manufacturer does not necessarily directly practice every step of a patient-use method claim merely by making or selling the product. However, product labeling that instructs buccal, sublingual, or gingival administration can create inducement exposure if the formulation satisfies the remaining limitations.

The claim is less likely to reach a product that merely contains fentanyl and is placed in the mouth without the claimed absorption-enhancing system. The patent's strongest technical distinction is the combination of saliva-triggered effervescence and pH adjustment.

What is the Orange Book status of U.S. Patent 6,974,590?

The patent is associated with the Cima/Cephalon oral transmucosal fentanyl technology and has been relevant to the patent estate surrounding Fentora, the fentanyl buccal tablet approved under NDA 021691. FDA Orange Book treatment is product-specific. A patent's historical association with a product does not establish that it remains listed for every fentanyl product or that it covers every approved formulation.

The Orange Book must be analyzed by:

NDA number.
Drug product.
Patent number.
Use code.
Listed expiration date.
Any delisting, correction, or regulatory update.

For Fentora, the relevant regulatory question is whether the patent was listed with a method-of-use code covering the approved fentanyl buccal administration method. A method-of-use listing does not automatically cover a different fentanyl dosage form, a different route, or a product approved under another NDA.

FDA's Orange Book framework also distinguishes listed patents from regulatory exclusivity. Patent listing can trigger a Paragraph IV notice process, but listing does not establish patent validity or infringement.[1]

When did U.S. Patent 6,974,590 lose exclusivity?

The patent issued on December 13, 2005. Its enforceable term is governed by the earliest effective nonprovisional filing date, subject to patent-term adjustment and any applicable patent-term extension. The issue date is not the expiration date.

As of 2026, the ordinary patent term has ended. The patent therefore should not be treated as a current long-term barrier to generic development. Any transaction, launch analysis, or litigation position should use the USPTO Patent Center term calculation and maintenance record as the controlling source.[2]

The patent's historical commercial significance remains relevant because it may have affected earlier Paragraph IV filings, settlements, launch timing, and the design of later fentanyl products. Its expiration does not eliminate separate patents covering later formulations, manufacturing processes, delivery systems, or approved uses.

Which competing fentanyl products are relevant?

The main U.S. oral and transmucosal fentanyl products include:

Product	Dosage form and route	Relevance to this patent
Fentora	Buccal tablet	Closest commercial technology profile
Actiq	Oral transmucosal lozenge on an applicator	Potentially relevant only if the claimed effervescent and pH limitations are present
Abstral	Sublingual tablet	Route potentially covered, but formulation must satisfy claim 1
Subsys	Sublingual spray	Generally outside the solid dosage-form limitation
Onsolis	Buccal film	Requires product-specific analysis
Lazanda	Nasal spray	Outside the oral-mucosal route
Generic fentanyl buccal or sublingual products	Product-specific	Risk depends on formulation, label, and route

Fentora is the closest reference point because the patent's claim architecture corresponds to an effervescent, pH-modified oral transmucosal tablet technology. Abstral and other sublingual products require separate formulation analysis.

What formulation patents and related IP create additional barriers?

Expiration of 6,974,590 does not mean the fentanyl oral-transmucosal field is free of IP constraints. Relevant patent categories include:

Formulation patents

These may cover:

Effervescent acid-base systems.
Alkaline microenvironments.
Rapidly disintegrating tablets.
Mucoadhesive compositions.
Taste-masking systems.
Fentanyl particle engineering.
Buccal films.
Sublingual sprays.
Controlled-release or multilayer dosage forms.

Method-of-use patents

Later patents may cover:

Breakthrough cancer pain.
Opioid-tolerant patients.
Dose titration.
Administration timing.
Route-specific use.
Risk-mitigation procedures combined with a product.

Manufacturing patents

Manufacturing barriers may involve:

Direct compression.
Moisture-controlled processing.
Fentanyl content uniformity.
Low-dose blend segregation control.
Effervescent excipient compatibility.
Tablet packaging and stability.
High-potency containment.

These rights are separate from the claims of 6,974,590. A generic applicant can avoid this patent and still face other listed or unlisted patent claims.

Which companies challenged or competed with the technology?

The competitive field has included Cephalon, later part of Teva, as the principal Fentora commercial organization; Cima Labs as the original technology developer; and manufacturers developing generic or competing fentanyl products through ANDA, 505(b)(2), or new-drug pathways.

Relevant competitors have included companies associated with generic fentanyl tablets, sublingual products, buccal films, and sprays. Paragraph IV exposure depends on the specific NDA or ANDA, listed patents, and use codes. A company may challenge one patent while certifying that it will not market the approved use covered by another patent.

Public records should be read separately for:

ANDA number.
Paragraph IV notice date.
Declaratory-judgment litigation.
Hatch-Waxman infringement action.
Settlement terms.
Agreed launch date.
Authorized-generic arrangements.
Whether the applicant ultimately received approval.

A patent number alone does not establish that a particular company challenged this patent.

What is the current generic-launch risk?

The direct barrier presented by U.S. Patent 6,974,590 is low after expiration. The remaining launch risks are more likely to arise from:

Other unexpired Fentora patents.
Formulation patents covering the generic's actual composition.
Method-of-use listings and carve-out limitations.
REMS or opioid-risk requirements.
Drug-substance sourcing.
Content uniformity and stability.
Controlled-substance manufacturing compliance.
ANDA approval timing.
Commercial differentiation against established fentanyl products.

A generic applicant that uses a non-effervescent formulation, a different pH strategy, or a spray or film dosage form may reduce exposure to this patent but cannot assume freedom to operate without reviewing the broader family and later continuation patents.

How strong is the patent estate for this technology?

The patent is technically coherent because it links the formulation mechanism to the administration method. Its strongest features are:

Specific oral transmucosal route coverage.
A quantified effervescent-agent range.
A pH-adjustment requirement.
Functional language tied to enhanced fentanyl absorption.
Dependent claims directed to commercially relevant buccal and sublingual routes.

Its weaknesses include:

No dose limitation.
No named excipient requirement.
No specific tablet architecture.
Functional language that may require experimental proof.
Potential disputes over "about 5%" and "about 80%."
Method-claim enforcement complexity.
Expiration of the patent term.

The patent was strongest against products that intentionally reproduced the Cima oral-effervescent technology. It was materially weaker against non-effervescent products, sprays, patches, nasal systems, and formulations using a different absorption mechanism.

Key Takeaways

U.S. Patent 6,974,590 covers a method of administering fentanyl through the oral mucosa using a solid dosage form with a saliva-activated effervescent agent and pH-adjusting substance.
Claim 1 requires an effervescent-agent concentration of about 5% to 80% by weight.
Claims 2 through 4 cover buccal, sublingual, and gingival administration.
Claims 7 through 9 focus on a basic pH-adjustment system producing a neutral or slightly alkaline absorption environment.
The patent does not broadly cover all fentanyl oral, buccal, or sublingual products.
Fentora is the closest commercial product for scope analysis.
The patent's ordinary term has ended by 2026, subject to the USPTO's final patent-term calculation.
Separate formulation, method-of-use, manufacturing, and continuation patents may still affect generic entry.
Orange Book status must be evaluated by NDA, listed patent, use code, and expiration record.
The principal technical design-around options are a non-effervescent formulation, a different pH strategy, or a different dosage form or delivery route.

FAQs About U.S. Patent 6,974,590

Does U.S. Patent 6,974,590 cover all fentanyl buccal tablets?

No. The tablet must also use the claimed saliva-activated effervescent agent in the claimed approximate concentration range and contain a pH-adjusting substance.

Can a fentanyl sublingual spray infringe this patent?

A sublingual spray generally does not meet the solid oral dosage-form limitation. Other patents may still apply to the spray.

Is fentanyl citrate specifically covered?

Fentanyl citrate can fall within the phrase "fentanyl or a pharmaceutically acceptable salt thereof," provided the product satisfies the other limitations.

Does a neutral pH have to be measured in the finished tablet?

Not necessarily. Claims 8 and 9 refer to the pH at the site of absorption. The relevant testing protocol and claim construction would determine how that limitation is applied.

Does patent expiration eliminate all barriers to a generic Fentora product?

No. Later patents, formulation patents, method-of-use patents, regulatory exclusivity, manufacturing requirements, and controlled-substance compliance can remain relevant after expiration of 6,974,590.

References

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
U.S. Patent No. 6,974,590. (2005). Method of administration of fentanyl across the oral mucosa. U.S. Patent and Trademark Office.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (n.d.). Fentora prescribing information. FDA.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	350017	⤷ Start Trial
Austria	433745	⤷ Start Trial
Austria	434432	⤷ Start Trial
Austria	548028	⤷ Start Trial
Australia	4019400	⤷ Start Trial
Australia	4488700	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,974,590

Summary for Patent: 6,974,590